RxDoctor Payments Data

Charmaine Browne, MD

Dermatology · McAllen, TXNPI 1992786339

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Arcutis Biotherapeutics, Inc. at 36.9% of the total. Reporting peaked in 2023 at $3,864 and has fallen 80.4% since, to $759 in 2025.

$8,228in general payments, 2019–2025

Across 279 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arcutis Biotherapeutics, Inc.$3K
  • Novartis$1K
  • AbbVie$703
  • Johnson & Johnson$684
  • Sanofi$638
  • UCB, Inc.$498
  • plus $2K from 20 others
$86,477in research payments, 2019–2025

Across 21 payments — averaging $4117.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$57K
  • Sanofi US Services Inc.$20K
  • AbbVie$9K

What the payments were for

  • Consulting fees$2,75033%
  • Food & beverage$4,80758%
  • Education$6718%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,228 in reported general payments places this provider in the 65th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas →

Medicare billing

Part B allowed, 2024
$34,620
Medicare patients
161
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab34$252,009
Cosentyx Unoready PenSecukinumab12$132,655
Cosentyx Sensoready (2 Pens)Secukinumab11$79,378
Dupixent PenDupilumab17$64,810
OpzeluraRuxolitinib Phosphate11$21,502
Ivermectin12$2,959
Clobetasol Propionate43$1,880
Pentoxifylline12$818
Ciclopirox15$644
Ketoconazole15$239
Triamcinolone Acetonide28$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$137$21,50211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,098 dermatology providers in Texas.

Other dermatology in McAllen

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →